Literature DB >> 9455805

Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents.

J Céraline1, G Deplanque, B Duclos, J M Limacher, A Hajri, F Noel, C Orvain, T Frébourg, C Klein-Soyer, J P Bergerat.   

Abstract

p53 mutations are found in about 70% of human cancers. In order to evaluate the role of these mutations in response to chemotherapeutic agents, it is important to distinguish between p53 response to DNA-damaging agents in normal and in tumour cells. Here, using normal human fibroblasts (NHFs), we show that cisplatin and UV radiation induce G2/M arrest which is temporally linked to p53-protein induction. To study the contribution of p53 to this G2/M arrest, we inhibited p53 induction in NHFs using p53 anti-sense oligonucleotides. Following exposure of NHFs to UV radiation, the inhibition of p53-protein induction leads to a greater accumulation of cells in the G2/M phase, but also to a decreased fraction of cells in the G1 phase. We propose that p53 does not induce G2/M arrest directly, and that the extent of this arrest may depend on the fraction of cells that do not stop at the G1 phase following exposure to DNA-damaging agents. Furthermore, inhibition of p53-protein induction leads to increased sensitivity of NHFs to UV radiation. These results suggest that inhibition of p53 protein enhances sensitivity to DNA-damaging agents in normal human cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9455805     DOI: 10.1002/(sici)1097-0215(19980130)75:3<432::aid-ijc17>3.0.co;2-a

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Authors:  T Megha; F Ferrari; A Benvenuto; C Bellan; A V Lalinga; S Lazzi; S Bartolommei; G Cevenini; L Leoncini; P Tosi
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

2.  Mechanisms of G2 arrest in response to overexpression of p53.

Authors:  W R Taylor; S E DePrimo; A Agarwal; M L Agarwal; A H Schönthal; K S Katula; G R Stark
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

3.  p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling.

Authors:  Andreas Sturm; Jugoh Itoh; James W Jacobberger; Claudio Fiocchi
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation.

Authors:  Ankita Leekha; Bahadur S Gurjar; Aakriti Tyagi; Moshahid A Rizvi; Anita K Verma
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-09       Impact factor: 4.553

5.  hSSB1 regulates both the stability and the transcriptional activity of p53.

Authors:  Shuangbing Xu; Yuanzhong Wu; Qiong Chen; Jingying Cao; Kaishun Hu; Jianjun Tang; Yi Sang; Fenju Lai; Li Wang; Ruhua Zhang; Sheng-Ping Li; Yi-Xin Zeng; Yuxin Yin; Tiebang Kang
Journal:  Cell Res       Date:  2012-11-27       Impact factor: 25.617

6.  Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.

Authors:  R A Bras-Gonçalves; C Rosty; P Laurent-Puig; P Soulié; B Dutrillaux; M F Poupon
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients.

Authors:  C Kihara; T Seki; Y Furukawa; H Yamana; Y Kimura; P van Schaardenburgh; K Hirata; Y Nakamura
Journal:  Jpn J Cancer Res       Date:  2000-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.